<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36979502</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2218-273X</ISSN><JournalIssue CitedMedium="Internet"><Volume>13</Volume><Issue>3</Issue><PubDate><Year>2023</Year><Month>Mar</Month><Day>20</Day></PubDate></JournalIssue><Title>Biomolecules</Title><ISOAbbreviation>Biomolecules</ISOAbbreviation></Journal><ArticleTitle>Association between Inflammation and Thrombotic Pathway Link with Pathogenesis of Depression and Anxiety in SLE Patients.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">567</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/biom13030567</ELocationID><Abstract><AbstractText>As a complication of systemic lupus erythematosus (SLE), the neuropsychiatric form may manifest with neurological and psychiatric symptoms. Diagnosing neuropsychiatric SLE can be challenging due to the heterogeneity of this disease manifestation and the possibilities of investigation. This research aims to identify the possible associations between inflammation and thrombotic biomarkers alongside anxiety and/or depression manifestations in SLE patients. A group of 65 outpatients were investigated regarding the levels of depression, anxiety, disability, quality of life and other specific serum biomarkers linked with inflammation or coagulopathies. The results showed severe depression in eight participants, moderate depression in 22 (33.85%), and 26 (40%) subjects with mild depression. Anxiety was more prevalent within 64 participants (98.46%), while a degree of disability was reported by 52 participants (80%). Quality of life evaluated by EQ5D revealed a medium value of 1.57, and EQ5D VAS health medium value was 57.95 and was correlated with anxiety. A strong positive correlation between depression, anxiety and antibodies associated with anti-cardiolipin and anti beta2 glycoprotein I antibodies, lupus anticoagulant, ICAM-1, low C4 a and anti-ribosomal P antibodies were identified. These data results suggest that autoimmune/inflammatory and ischemic/thrombotic pathways could contribute to depression and anxiety as neuropsychiatric SLE manifestations.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Duca</LastName><ForeName>Liliana</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-3062-766X</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Transilvania University of Bra&#x15f;ov, 500036 Bra&#x15f;ov, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Immunology, County Emergency Clinic Hospital, 500326 Bra&#x15f;ov, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roman</LastName><ForeName>Nadinne</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0002-4263-2589</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, Transilvania University of Bra&#x15f;ov, 500036 Bra&#x15f;ov, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hospital of Psychiatry and Neurology of Brasov, 500123 Bra&#x15f;ov, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Teodorescu</LastName><ForeName>Andreea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Transilvania University of Bra&#x15f;ov, 500036 Bra&#x15f;ov, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hospital of Psychiatry and Neurology of Brasov, 500123 Bra&#x15f;ov, Romania.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ifteni</LastName><ForeName>Petru</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Faculty of Medicine, Transilvania University of Bra&#x15f;ov, 500036 Bra&#x15f;ov, Romania.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Hospital of Psychiatry and Neurology of Brasov, 500123 Bra&#x15f;ov, Romania.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Biomolecules</MedlineTA><NlmUniqueID>101596414</NlmUniqueID><ISSNLinking>2218-273X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012269">Ribosomal Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001323">Autoantibodies</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015415">Biomarkers</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003863" MajorTopicYN="N">Depression</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012269" MajorTopicYN="N">Ribosomal Proteins</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020945" MajorTopicYN="Y">Lupus Vasculitis, Central Nervous System</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001323" MajorTopicYN="N">Autoantibodies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001007" MajorTopicYN="N">Anxiety</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015415" MajorTopicYN="N">Biomarkers</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">anxiety</Keyword><Keyword MajorTopicYN="N">depression</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">systemic lupus erythematosus</Keyword><Keyword MajorTopicYN="N">thrombotic</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>1</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>3</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>3</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>29</Day><Hour>1</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36979502</ArticleId><ArticleId IdType="pmc">PMC10046775</ArticleId><ArticleId IdType="doi">10.3390/biom13030567</ArticleId><ArticleId IdType="pii">biom13030567</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Liu Y., Tu Z., Zhang X., Du K., Xie Z., Lin Z. Pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus: A review. Front. Cell Dev. Biol. 2022;10:998328. doi: 10.3389/fcell.2022.998328.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2022.998328</ArticleId><ArticleId IdType="pmc">PMC9484581</ArticleId><ArticleId IdType="pubmed">36133921</ArticleId></ArticleIdList></Reference><Reference><Citation>Zardi E.M., Giorgi C., Zardi D.M. Diagnostic approach to neuropsychiatric lupus erythematosus: What should we do? Postgrad. Med. 2018;130:536&#x2013;547. doi: 10.1080/00325481.2018.1492309.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/00325481.2018.1492309</ArticleId><ArticleId IdType="pubmed">29940795</ArticleId></ArticleIdList></Reference><Reference><Citation>Liang M.H., Corzillius M., Bae S.C., Lew R.A., Fortin P.R., Gordon C., Isenberg D., Alarc&#xf3;n G.S., Straaton K.V., Denburg J., et al. The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum. 1999;42:599&#x2013;608. doi: 10.1002/1529-0131(199904)42:43.0.CO;2-F.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199904)42:43.0.CO;2-F</ArticleId><ArticleId IdType="pubmed">10211873</ArticleId></ArticleIdList></Reference><Reference><Citation>Muscal E., Brey R.L. Neurologic Manifestations of Systemic Lupus Erythematosus in Children and Adults. Neurol. Clin. 2010;28:61&#x2013;73. doi: 10.1016/j.ncl.2009.09.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ncl.2009.09.004</ArticleId><ArticleId IdType="pmc">PMC2981505</ArticleId><ArticleId IdType="pubmed">19932376</ArticleId></ArticleIdList></Reference><Reference><Citation>Kivity S., Agmon-Levin N., Zandman-Goddard G., Chapman J., Shoenfeld Y. Neuropsychiatric lupus: A mosaic of clinical presentations. BMC Med. 2015;13:43. doi: 10.1186/s12916-015-0269-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12916-015-0269-8</ArticleId><ArticleId IdType="pmc">PMC4349748</ArticleId><ArticleId IdType="pubmed">25858312</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertsias G.K., Ioannidis J.P., Aringer M., Bollen E., Bombardieri S., Bruce I.N., Cervera R., Dalakas M., Doria A., Hanly J.G., et al. EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: Report of a task force of the EULAR standing committee for clinical affairs. Ann. Rheum. Dis. 2010;69:2074&#x2013;2082. doi: 10.1136/ard.2010.130476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2010.130476</ArticleId><ArticleId IdType="pubmed">20724309</ArticleId></ArticleIdList></Reference><Reference><Citation>Aranow C., Diamond B., Mackay M. Glutamate Receptor Biology and its Clinical Significance in Neuropsychiatric Systemic Lupus Erythematosus. Rheum. Dis. Clin. N. Am. 2010;36:187&#x2013;201. doi: 10.1016/j.rdc.2009.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.rdc.2009.12.007</ArticleId><ArticleId IdType="pmc">PMC2837540</ArticleId><ArticleId IdType="pubmed">20202599</ArticleId></ArticleIdList></Reference><Reference><Citation>Moustafa A.T., Moazzami M., Engel L., Bangert E., Hassanein M., Marzouk S., Kravtsenyuk M., Fung W., Eder L., Su J., et al. Prevalence and metric of depression and anxiety in systemic lupus erythematosus: A systematic review and meta-analysis. Semin. Arthritis Rheum. 2020;50:84&#x2013;94. doi: 10.1016/j.semarthrit.2019.06.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2019.06.017</ArticleId><ArticleId IdType="pubmed">31303437</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi S.T., Kang J.I., Park I.-H., Lee Y.W., Song J.-S., Park Y.-B., Lee S.-K. Subscale analysis of quality of life in patients with systemic lupus erythematosus: Association with depression, fatigue, disease activity and damage. Clin. Exp. Rheumatol. 2012;30:665&#x2013;672.</Citation><ArticleIdList><ArticleId IdType="pubmed">22704691</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang S., Li M., Zhang L., Wang Z., Wang Q., You H., Wang Y., Li M., Zeng X. Clinical Features and Outcomes of Neuropsychiatric Systemic Lupus Erythematosus in China. J. Immunol. Res. 2021;2021:1349042. doi: 10.1155/2021/1349042.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/1349042</ArticleId><ArticleId IdType="pmc">PMC7834780</ArticleId><ArticleId IdType="pubmed">33532504</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwartz N., Stock A.D., Putterman C. Neuropsychiatric lupus: New mechanistic insights and future treatment directions. Nat. Rev. Rheumatol. 2019;15:137&#x2013;152. doi: 10.1038/s41584-018-0156-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41584-018-0156-8</ArticleId><ArticleId IdType="pmc">PMC8023338</ArticleId><ArticleId IdType="pubmed">30659245</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen D., Rijnink E.C., Nabuurs R.J.A., Steup-Beekman G.M., Versluis M.J., Emmer B.J., Zandbergen M., van Buchem M.A., Allaart C.F., Wolterbeek R., et al. Brain histopathology in patients with systemic lupus erythematosus: Identification of lesions associated with clinical neuropsychiatric lupus syndromes and the role of complement. Rheumatology. 2017;56:77&#x2013;86. doi: 10.1093/rheumatology/kew341.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/kew341</ArticleId><ArticleId IdType="pubmed">28028157</ArticleId></ArticleIdList></Reference><Reference><Citation>Sato S., Temmoku J., Fujita Y., Yashiro-Furuya M., Matsuoka N., Asano T., Kobayashi H., Watanabe H., Migita K. Autoantibodies associated with neuropsychiatric systemic lupus erythematosus: The quest for symptom-specific biomarkers. Fukushima J. Med. Sci. 2020;66:1&#x2013;9. doi: 10.5387/fms.2020-02.</Citation><ArticleIdList><ArticleId IdType="doi">10.5387/fms.2020-02</ArticleId><ArticleId IdType="pmc">PMC7269884</ArticleId><ArticleId IdType="pubmed">32173681</ArticleId></ArticleIdList></Reference><Reference><Citation>Ho R.C., Thiaghu C., Ong H., Lu Y., Ho C.S., Tam W.W., Zhang M.W. A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. Autoimmun. Rev. 2016;15:124&#x2013;138. doi: 10.1016/j.autrev.2015.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2015.10.003</ArticleId><ArticleId IdType="pubmed">26497108</ArticleId></ArticleIdList></Reference><Reference><Citation>Sarwar S., Mohamed A.S., Rogers S., Sarmast S.T., Kataria S., Mohamed K.H., Khalid M.Z., Saeeduddin M.O., Shiza S.T., Ahmad S., et al. Neuropsychiatric Systemic Lupus Erythematosus: A 2021 Update on Diagnosis, Management, and Current Challenges. Cureus. 2021;13:e17969. doi: 10.7759/cureus.17969.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.17969</ArticleId><ArticleId IdType="pmc">PMC8516357</ArticleId><ArticleId IdType="pubmed">34667659</ArticleId></ArticleIdList></Reference><Reference><Citation>Sibbitt W.L., Brooks W.M., Kornfeld M., Hart B.L., Bankhurst A.D., Roldan C.A. Magnetic Resonance Imaging and Brain Histopathology in Neuropsychiatric Systemic Lupus Erythematosus. Semin. Arthritis Rheum. 2010;40:32&#x2013;52. doi: 10.1016/j.semarthrit.2009.08.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2009.08.005</ArticleId><ArticleId IdType="pmc">PMC3586567</ArticleId><ArticleId IdType="pubmed">19880162</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinan T.G. Inflammatory markers in depression. Curr. Opin. Psychiatry. 2009;22:32&#x2013;36. doi: 10.1097/YCO.0b013e328315a561.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/YCO.0b013e328315a561</ArticleId><ArticleId IdType="pubmed">19122532</ArticleId></ArticleIdList></Reference><Reference><Citation>Nourshargh S., Alon R. Leukocyte Migration into Inflamed Tissues. Immunity. 2014;41:694&#x2013;707. doi: 10.1016/j.immuni.2014.10.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2014.10.008</ArticleId><ArticleId IdType="pubmed">25517612</ArticleId></ArticleIdList></Reference><Reference><Citation>Scherlinger M., Guillotin V., Douchet I., Vacher P., Boizard-Moracchini A., Guegan J.-P., Garreau A., Merillon N., Vermorel A., Ribeiro E., et al. Selectins impair regulatory T cell function and contribute to systemic lupus erythematosus pathogenesis. Sci. Transl. Med. 2021;13:eabi4994. doi: 10.1126/scitranslmed.abi4994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/scitranslmed.abi4994</ArticleId><ArticleId IdType="pubmed">34193612</ArticleId></ArticleIdList></Reference><Reference><Citation>Nowak K., Gumkowska-Sroka O., Kotyla P. Adhesion molecules: A way to understand lupus. Rheumatology. 2022;60:133&#x2013;141. doi: 10.5114/reum.2022.115664.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/reum.2022.115664</ArticleId><ArticleId IdType="pmc">PMC9238314</ArticleId><ArticleId IdType="pubmed">35782027</ArticleId></ArticleIdList></Reference><Reference><Citation>Andrianova I.A., Khabirova A.I., Ponomareva A.A., Peshkova A.D., Evtugina N.G., Le Minh G., Sibgatullin T.B., Weisel J.W., Litvinov R.I. Chronic Immune Platelet Activation Is Followed by Platelet Refractoriness and Impaired Contractility. Int. J. Mol. Sci. 2022;23:7336. doi: 10.3390/ijms23137336.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms23137336</ArticleId><ArticleId IdType="pmc">PMC9266422</ArticleId><ArticleId IdType="pubmed">35806341</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo Liu R.N., Cheng Q.Y., Zhou H.Y., Li B.Z., Ye D.Q. Elevated blood and urinary ICAM-1 is a biomarker for systemic lupus erythematosus: A systematic review and meta-analysis. Immunol. Investig. 2020;49:15&#x2013;31. doi: 10.1080/08820139.2019.1624769.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/08820139.2019.1624769</ArticleId><ArticleId IdType="pubmed">31298049</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z., Xiao J., Song H., Chen Q., Han H., Li J., Zhang L., He Y., Wei M. Evaluation of coagulation disorders by thromboelastography in children with systemic lupus erythematosus. Lupus. 2019;28:181&#x2013;188. doi: 10.1177/0961203318819137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318819137</ArticleId><ArticleId IdType="pubmed">30563423</ArticleId></ArticleIdList></Reference><Reference><Citation>Milaneschi Y., Kappelmann N., Ye Z., Lamers F., Moser S., Jones P.B., Burgess S., Penninx B.W., Khandaker G. Association of inflammation with depression and anxiety: Evidence for symptom-specificity and potential causality from UK Biobank and NESDA cohorts. Mol. Psychiatry. 2021;26:7393&#x2013;7402. doi: 10.1038/s41380-021-01188-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01188-w</ArticleId><ArticleId IdType="pmc">PMC8873022</ArticleId><ArticleId IdType="pubmed">34135474</ArticleId></ArticleIdList></Reference><Reference><Citation>De Hert M., Detraux J., Vancampfort D. The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin. Neurosci. 2018;20:31&#x2013;40. doi: 10.31887/DCNS.2018.20.1/mdehert.</Citation><ArticleIdList><ArticleId IdType="doi">10.31887/DCNS.2018.20.1/mdehert</ArticleId><ArticleId IdType="pmc">PMC6016051</ArticleId><ArticleId IdType="pubmed">29946209</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoirisch-Clapauch S., Nardi A.E., Gris J.-C., Brenner B. Coagulation and Mental Disorders. Rambam Maimonides Med. J. 2014;5:e0036. doi: 10.5041/RMMJ.10170.</Citation><ArticleIdList><ArticleId IdType="doi">10.5041/RMMJ.10170</ArticleId><ArticleId IdType="pmc">PMC4222425</ArticleId><ArticleId IdType="pubmed">25386352</ArticleId></ArticleIdList></Reference><Reference><Citation>Galli M., Luciani D., Bertolini G., Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood. 2003;101:1827&#x2013;1832. doi: 10.1182/blood-2002-02-0441.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2002-02-0441</ArticleId><ArticleId IdType="pubmed">12393574</ArticleId></ArticleIdList></Reference><Reference><Citation>Borchers A.T., Aoki C.A., Naguwa S.M., Keen C.L., Shoenfeld Y., Gershwin M.E. Neuropsychiatric features of syste-mic lupus erythematosus. Autoimmun. Rev. 2005;4:329&#x2013;344. doi: 10.1016/j.autrev.2005.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2005.01.008</ArticleId><ArticleId IdType="pubmed">16081024</ArticleId></ArticleIdList></Reference><Reference><Citation>Shrivastava A., Dwivedi S., Aggarwal A., Misra R. Anti-cardiolipin and anti-beta2 glycoprotein I antibodies in Indian patients with systemic lupus erythematosus: Association with the presence of seizures. Lupus. 2001;10:45&#x2013;50. doi: 10.1191/096120301671577528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/096120301671577528</ArticleId><ArticleId IdType="pubmed">11243509</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi M.Y., FitzPatrick R.D., Buhler K., Mahler M., Fritzler M.J. A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus. Autoimmun. Rev. 2020;19:102463. doi: 10.1016/j.autrev.2020.102463.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102463</ArticleId><ArticleId IdType="pubmed">31927088</ArticleId></ArticleIdList></Reference><Reference><Citation>Arinuma Y., Kikuchi H., Hirohata S. Anti-ribosomal P protein antibodies influence mortality of patients with diffuse psychiatric/neuropsychological syn-dromes in systemic lupus erythematous involving a severe form of the disease. Mod. Rheumatol. 2019;29:612&#x2013;618. doi: 10.1080/14397595.2018.1508801.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14397595.2018.1508801</ArticleId><ArticleId IdType="pubmed">30075696</ArticleId></ArticleIdList></Reference><Reference><Citation>Petri M., Orbai A.-M., Alarc&#xf3;n G.S., Gordon C., Merrill J.T., Fortin P.R., Bruce I.N., Isenberg D., Wallace D.J., Nived O., et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64:2677&#x2013;2686. doi: 10.1002/art.34473.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.34473</ArticleId><ArticleId IdType="pmc">PMC3409311</ArticleId><ArticleId IdType="pubmed">22553077</ArticleId></ArticleIdList></Reference><Reference><Citation>Duca L., Roman N.A., Miron A., Teodorescu A., Dima L., Ifteni P. WHODAS Assessment Feasibility and Mental Health Impact on Functional Disability in Systemic Lupus Erythematosus. Healthcare. 2022;10:1053. doi: 10.3390/healthcare10061053.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/healthcare10061053</ArticleId><ArticleId IdType="pmc">PMC9222861</ArticleId><ArticleId IdType="pubmed">35742104</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.L., Wu B., Zhu L.A., Leng L., Bucala R., Lu L.J. Construct and Criterion Validity of the Euro Qol-5D in Patients with Systemic Lupus Erythematosus. PLoS ONE. 2014;9:e98883. doi: 10.1371/journal.pone.0098883.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0098883</ArticleId><ArticleId IdType="pmc">PMC4043925</ArticleId><ArticleId IdType="pubmed">24892282</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. The assessment of anxiety states by rating. Br. J. Med. Psychol. 1959;32:50&#x2013;55. doi: 10.1111/j.2044-8341.1959.tb00467.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.2044-8341.1959.tb00467.x</ArticleId><ArticleId IdType="pubmed">13638508</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry. 1960;23:56&#x2013;62. doi: 10.1136/jnnp.23.1.56.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.23.1.56</ArticleId><ArticleId IdType="pmc">PMC495331</ArticleId><ArticleId IdType="pubmed">14399272</ArticleId></ArticleIdList></Reference><Reference><Citation>Liao J., Kang J., Li F., Li Q., Wang J., Tang Q., Ni Mao N., Li S., Xie X. A cross-sectional study on the association of anxiety and depression with the disease activity of systemic lupus erythematosus. BMC Psychiatry. 2022;22:591. doi: 10.1186/s12888-022-04236-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12888-022-04236-z</ArticleId><ArticleId IdType="pmc">PMC9443011</ArticleId><ArticleId IdType="pubmed">36064377</ArticleId></ArticleIdList></Reference><Reference><Citation>Chalhoub N.E., Luggen M.E. Depression-, Pain-, and Health-Related Quality of Life in Patients with Systemic Lupus Erythematosus. Int. J. Rheumatol. 2022;2022:6290736. doi: 10.1155/2022/6290736.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2022/6290736</ArticleId><ArticleId IdType="pmc">PMC9098355</ArticleId><ArticleId IdType="pubmed">35572065</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumner L.A., Olmstead R., Azizoddin D.R., Ormseth S.R., Draper T.L., Ayeroff J.R., Zamora-Racaza G., Weisman M.H., Nicassio P.M. The contributions of socioeconomic status, perceived stress, and depression to disability in adults with systemic lupus erythematosus. Disabil. Rehabil. 2019;42:1264&#x2013;1269. doi: 10.1080/09638288.2018.1522550.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09638288.2018.1522550</ArticleId><ArticleId IdType="pubmed">30776317</ArticleId></ArticleIdList></Reference><Reference><Citation>Yousef A.A., Mohamed F.Y., Boraey N.F., Akeel N.E., Soliman A.A., Waked N.M., Hashem M.I., Shehata H., Fahmy D.S., Ismael A., et al. Association of Plasminogen Activator Inhibitor 1 (PAI-1) 4G/5G Polymorphism and Susceptibility to SLE in Egyptian Children and Adolescents: A Multicenter Study. J. Inflamm. Res. 2020;13:1103&#x2013;1111. doi: 10.2147/JIR.S277373.</Citation><ArticleIdList><ArticleId IdType="doi">10.2147/JIR.S277373</ArticleId><ArticleId IdType="pmc">PMC7754263</ArticleId><ArticleId IdType="pubmed">33363394</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoirisch-Clapauch S. Mechanisms affecting brain remodeling in depression: Do all roads lead to impaired fibrinolysis? Mol. Psychiatry. 2022;27:525&#x2013;533. doi: 10.1038/s41380-021-01264-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41380-021-01264-1</ArticleId><ArticleId IdType="pubmed">34404914</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeltsch-David H., Muller S. Neuropsychiatric systemic lupus erythematosus: Pathogenesis and biomarkers. Nat. Rev. Neurol. 2014;10:579&#x2013;596. doi: 10.1038/nrneurol.2014.148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrneurol.2014.148</ArticleId><ArticleId IdType="pubmed">25201240</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolfe F., Michaud K., Li T., Katz R.S. EQ-5D and SF-36 Quality of Life Measures in Systemic Lupus Erythematosus: Comparisons with Rheumatoid Arthritis, Noninflammatory Rheumatic Disorders, and Fibromyalgia. J. Rheumatol. 2010;37:296&#x2013;304. doi: 10.3899/jrheum.090778.</Citation><ArticleIdList><ArticleId IdType="doi">10.3899/jrheum.090778</ArticleId><ArticleId IdType="pubmed">20032098</ArticleId></ArticleIdList></Reference><Reference><Citation>Short H., Al Sayah F., Ohinmaa A., Johnson J.A. The performance of the EQ-5D-3L in screening for anxiety and depressive symptoms in hospital and community settings. Health Qual. Life Outcomes. 2021;19:96. doi: 10.1186/s12955-021-01731-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12955-021-01731-x</ArticleId><ArticleId IdType="pmc">PMC7977278</ArticleId><ArticleId IdType="pubmed">33741011</ArticleId></ArticleIdList></Reference><Reference><Citation>Osimo E.F., Pillinger T., Rodriguez I.M., Khandaker G.M., Pariante C.M., Howes O.D. Inflammatory markers in depression: A meta-analysis of mean differences and variability in 5166 patients and 5083 controls. Brain Behav. Immun. 2020;87:901&#x2013;909. doi: 10.1016/j.bbi.2020.02.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2020.02.010</ArticleId><ArticleId IdType="pmc">PMC7327519</ArticleId><ArticleId IdType="pubmed">32113908</ArticleId></ArticleIdList></Reference><Reference><Citation>Gris J.-C., Brenner B. Antiphospholipid Antibodies: Neuropsychiatric Presentations. Semin. Thromb. Hemost. 2013;39:935&#x2013;942. doi: 10.1016/S0049-3848(15)50445-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0049-3848(15)50445-3</ArticleId><ArticleId IdType="pubmed">24129681</ArticleId></ArticleIdList></Reference><Reference><Citation>Borowoy A.M., Pope J.E., Silverman E., Fortin P.R., Pineau C., Smith C.D., Arbillaga H., Gladman D., Urowitz M., Zummer M., et al. Neuropsychiatric Lupus: The Prevalence and Autoantibody Associations Depend on the Definition: Results from the 1000 Faces of Lupus Cohort. Semin. Arthritis Rheum. 2012;42:179&#x2013;185. doi: 10.1016/j.semarthrit.2012.03.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semarthrit.2012.03.011</ArticleId><ArticleId IdType="pubmed">22595642</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheldieva F., Reshetnyak T., Cherkasova M., Glukhova S., Lila A., Nasonov E. ab0496 should antibodies to domain i b2-glycoprotein 1 be investigated in patients with antiphospholipid syndrome (aps) and systemic lupus erythematosus (SLE)? Ann. Rheum. Dis. 2022;81:1374&#x2013;1375. doi: 10.1136/annrheumdis-2022-eular.2329.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2022-eular.2329</ArticleId><ArticleId IdType="pubmed">0</ArticleId></ArticleIdList></Reference><Reference><Citation>Elkhalifa M., Orbai A.-M., Magder L.S., Petri M., Alarc&#xf3;n G.S., Gordon C., Merrill J., Fortin P.R., Bruce I.N., Isenberg D., et al. Anti-beta 2 glycoprotein I IgA in the SLICC classification criteria dataset. Lupus. 2021;30:1283&#x2013;1288. doi: 10.1177/09612033211014248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/09612033211014248</ArticleId><ArticleId IdType="pubmed">33957797</ArticleId></ArticleIdList></Reference><Reference><Citation>Aso K., Kono M., Watanabe T., Shimizu Y., Ogata Y., Fujieda Y., Kato M., Oku K., Amengual O., Yasuda S., et al. Low C4 as a risk factor for severe neuropsychiatric flare in patients with systemic lupus erythematosus. Lupus. 2020;29:1238&#x2013;1247. doi: 10.1177/0961203320938453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203320938453</ArticleId><ArticleId IdType="pubmed">32635880</ArticleId></ArticleIdList></Reference><Reference><Citation>Magro-Checa C., Schaarenburg R.A., Beaart H.J.L., Huizinga T.W.J., Steup-Beekman G.M., Trouw L. Complement levels and anti-C1q autoantibodies in patients with neuropsychiatric systemic lupus erythematosus. Lupus. 2016;25:878&#x2013;888. doi: 10.1177/0961203316643170.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203316643170</ArticleId><ArticleId IdType="pubmed">27252265</ArticleId></ArticleIdList></Reference><Reference><Citation>Mehta N., Uchino K., Fakhran S., Sattar M.A., Branstetter B., 4th, Au K., Navratil J.S., Paul B., Lee M., Gallagher K.M., et al. Platelet C4d Is Associated with Acute Ischemic Stroke and Stroke Severity. Stroke. 2008;39:3236&#x2013;3241. doi: 10.1161/STROKEAHA.108.514687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/STROKEAHA.108.514687</ArticleId><ArticleId IdType="pubmed">18927458</ArticleId></ArticleIdList></Reference><Reference><Citation>Oku K., Atsumi T., Bohgaki M., Amengual O., Kataoka H., Horita T., Yasuda S., Koike T. Complement activation in patients with primary antiphospholipid syndrome. Ann. Rheum. Dis. 2008;68:1030&#x2013;1035. doi: 10.1136/ard.2008.090670.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/ard.2008.090670</ArticleId><ArticleId IdType="pubmed">18625630</ArticleId></ArticleIdList></Reference><Reference><Citation>Zanon C., Brenner R.E., Baptista M.N., Vogel D.L., Rubin M., Al-Darmaki F.R., Gon&#xe7;alves M., Heath P.J., Liao H.-Y., MacKenzie C.S., et al. Examining the Dimensionality, Reliability, and Invariance of the Depression, Anxiety, and Stress Scale-21 (DASS-21) Across Eight Countries. Assessment. 2021;28:1531&#x2013;1544. doi: 10.1177/1073191119887449.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1073191119887449</ArticleId><ArticleId IdType="pubmed">31916468</ArticleId></ArticleIdList></Reference><Reference><Citation>Staples L.G., Dear B.F., Gandy M., Fogliati V., Fogliati R., Karin E., Nielssen O., Titov N. Psychometric properties and clinical utility of brief measures of depression, anxiety, and general distress: The PHQ-2, GAD-2, and K-Gen. Hosp. Psychiatry. 2019;56:13&#x2013;18. doi: 10.1016/j.genhosppsych.2018.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.genhosppsych.2018.11.003</ArticleId><ArticleId IdType="pubmed">30508772</ArticleId></ArticleIdList></Reference><Reference><Citation>Aringer M., Johnson S.R. Classifying and diagnosing systemic lupus erythematosus in the 21st century. Rheumatology. 2020;59((Suppl. 5)):v4&#x2013;v11. doi: 10.1093/rheumatology/keaa379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keaa379</ArticleId><ArticleId IdType="pmc">PMC7719035</ArticleId><ArticleId IdType="pubmed">33280013</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>